Catalent (NYSE:CTLT) Lowered to Hold at Baird R W

Baird R W lowered shares of Catalent (NYSE:CTLT) from a strong-buy rating to a hold rating in a research report report published on Tuesday, Zacks.com reports.

CTLT has been the subject of several other reports. Royal Bank of Canada reissued a sector perform rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. StockNews.com initiated coverage on Catalent in a research report on Wednesday, September 18th. They issued a sell rating for the company. Robert W. Baird reissued a neutral rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday. Barclays lifted their price objective on Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research report on Friday, June 28th. Finally, William Blair reissued a market perform rating on shares of Catalent in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the stock. According to data from MarketBeat, Catalent has a consensus rating of Hold and a consensus price target of $59.83.

Catalent Stock Up 0.7 %

Shares of NYSE:CTLT opened at $60.14 on Tuesday. The firm has a market cap of $10.91 billion, a P/E ratio of -9.86, a P/E/G ratio of 2.32 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. Catalent has a 12-month low of $31.80 and a 12-month high of $61.20. The business has a fifty day simple moving average of $59.56 and a 200 day simple moving average of $57.27.

Catalent (NYSE:CTLT) last announced its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. Analysts predict that Catalent will post 0.85 earnings per share for the current year.

Insider Activity

In other news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Insiders sold a total of 13,409 shares of company stock worth $782,923 in the last three months. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

A number of hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC lifted its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalent during the 2nd quarter worth approximately $42,000. Mather Group LLC. bought a new position in shares of Catalent during the 1st quarter worth approximately $52,000. Longfellow Investment Management Co. LLC lifted its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.